• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[2型糖尿病与心血管危险因素:是否需要综合治疗?]

[Type 2 diabetes mellitus and cardiovascular risk factors: is comprehensive treatment required?].

作者信息

Nadal Josep Franch, Gutiérrez Pedro Conthe

机构信息

EAP Raval Sud-ICS (Barcelona) y redGDPS, Barcelona, España.

Sección de Medicina Interna, Hospital General Universitario Gregorio Marañón, Madrid, España.

出版信息

Med Clin (Barc). 2013 Sep;141 Suppl 2:7-13. doi: 10.1016/S0025-7753(13)70057-5.

DOI:10.1016/S0025-7753(13)70057-5
PMID:24444518
Abstract

Diabetes mellitus, especially type 2, is a metabolic disease involving the coexistence of several cardiovascular risk factors. Affected patients are therefore at high cardiovascular risk (2-3 times higher than that of men in the general population and 2-6 times higher than that of women). Cardiovascular disease is the main cause of death in the diabetic population, followed by cancer. Cardiovascular risk cannot be compared between diabetic patients and persons who have already shown one or more manifestations of cardiovascular disease (such as myocardial infarction). Single risk factors should be evaluated in combination with other risk factors and a person's cardiovascular risk should be individually assessed. Cardiovascular risk assessment in patients with diabetes through current calculations methods is complex because their ability to predict risk in individuals is very low. Studies such as that by Steno have demonstrated the validity of a comprehensive strategy to control all the risk factors present in persons with type 2 diabetes mellitus, which can reduce the development of micro- and macrovascular complications and mortality by almost 50%. The present article reviews each of the classical cardiovascular risk factors (hypertension, dyslipidemia, smoking, obesity, sedentariness) in relation to diabetes, as well as their recommended targets and the benefits of their control. In view of the above, a comprehensive approach is recommended to control the multiple risk factors that can coexist in persons with type 2 diabetes mellitus.

摘要

糖尿病,尤其是2型糖尿病,是一种涉及多种心血管危险因素并存的代谢性疾病。因此,受影响的患者心血管风险很高(比普通人群中的男性高2至3倍,比女性高2至6倍)。心血管疾病是糖尿病患者的主要死因,其次是癌症。糖尿病患者与已经出现一种或多种心血管疾病表现(如心肌梗死)的人之间的心血管风险无法进行比较。单一危险因素应与其他危险因素结合评估,并且应单独评估一个人的心血管风险。通过当前的计算方法对糖尿病患者进行心血管风险评估很复杂,因为这些方法预测个体风险的能力非常低。像斯滕诺(Steno)研究所表明的那样,全面控制2型糖尿病患者中存在的所有危险因素的策略是有效的,这可以将微血管和大血管并发症的发生以及死亡率降低近50%。本文回顾了与糖尿病相关的每种经典心血管危险因素(高血压、血脂异常、吸烟、肥胖、久坐不动),以及它们的推荐目标和控制这些因素的益处。鉴于上述情况,建议采用综合方法来控制2型糖尿病患者中可能并存的多种危险因素。

相似文献

1
[Type 2 diabetes mellitus and cardiovascular risk factors: is comprehensive treatment required?].[2型糖尿病与心血管危险因素:是否需要综合治疗?]
Med Clin (Barc). 2013 Sep;141 Suppl 2:7-13. doi: 10.1016/S0025-7753(13)70057-5.
2
Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study.性别相关的 2 型糖尿病老年患者初级保健中心血管危险因素控制差异:一项队列研究。
Can J Diabetes. 2018 Aug;42(4):365-371.e2. doi: 10.1016/j.jcjd.2017.08.248. Epub 2017 Oct 13.
3
[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].[心血管风险与心脏代谢风险:一项流行病学评估]
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S.
4
[Metabolic control or reduction of vascular risk with current treatments. What is the priority?].
Semergen. 2018 Jun;44 Suppl 1:26-32. doi: 10.1016/S1138-3593(18)30372-1.
5
Assessing cardiovascular risk factors and selecting agents to successfully treat patients with type 2 diabetes mellitus.评估心血管危险因素并选择药物以成功治疗2型糖尿病患者。
J Am Osteopath Assoc. 2011 Jul;111(7 Suppl 5):S2-12.
6
The role of fenofibrate in clinical practice.非诺贝特在临床实践中的作用。
Diab Vasc Dis Res. 2007 Sep;4 Suppl 3:S15-20. doi: 10.3132/dvdr.2007.053.
7
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].联合抗高血压和抗血脂治疗作为高心血管风险患者多药预防策略的支柱之一
Orv Hetil. 2008 Sep 28;149(39):1827-37. doi: 10.1556/OH.2008.28457.
8
Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.在临床实践环境中,使用艾塞那肽治疗的2型糖尿病和代谢综合征患者的血糖控制改善及心血管代谢危险因素的降低。
Diabetes Technol Ther. 2009 Jun;11(6):353-9. doi: 10.1089/dia.2008.0090.
9
[Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].[使用他汀类药物治疗的糖尿病患者的血脂异常。斯皮安地区DYSIS研究结果]
Med Clin (Barc). 2013 Nov 16;141(10):430-6. doi: 10.1016/j.medcli.2012.09.030. Epub 2012 Dec 12.
10
Preventing macrovascular disease in patients with type 2 diabetes mellitus.预防2型糖尿病患者的大血管疾病。
Am J Cardiovasc Drugs. 2003;3(4):283-97. doi: 10.2165/00129784-200303040-00007.

引用本文的文献

1
Is a Previously or Currently Reduced Testosterone Level in Male Patients with Type 2 Diabetes Mellitus a Risk Factor for the Development of Coronary Artery Disease? A Systematic Review and Meta-analysis.2型糖尿病男性患者既往或当前睾酮水平降低是冠状动脉疾病发生的危险因素吗?一项系统评价和荟萃分析。
Diabetes Ther. 2018 Jun;9(3):1061-1072. doi: 10.1007/s13300-018-0415-3. Epub 2018 Apr 4.
2
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.利拉鲁肽与利司那肽对比:西班牙2型糖尿病治疗中GLP-1受体激动剂疗法的长期成本效益
Diabetes Ther. 2017 Apr;8(2):401-415. doi: 10.1007/s13300-017-0239-6. Epub 2017 Feb 21.